Log in

NASDAQ:BMRABiomerica Stock Price, Forecast & News

$5.35
-0.08 (-1.47 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.35
Now: $5.35
$5.72
50-Day Range
$6.05
MA: $7.29
$8.89
52-Week Range
$2.05
Now: $5.35
$23.39
Volume320,220 shs
Average Volume329,184 shs
Market Capitalization$52.91 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.85
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BMRA
CUSIPN/A
Phone949-645-2111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.20 million
Book Value$0.41 per share

Profitability

Net Income$-2,390,000.00

Miscellaneous

Employees54
Market Cap$52.91 million
Next Earnings Date9/4/2020 (Estimated)
OptionableNot Optionable

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

How has Biomerica's stock been impacted by COVID-19 (Coronavirus)?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BMRA shares have increased by 84.5% and is now trading at $5.35. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biomerica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biomerica.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Friday, September 4th 2020. View our earnings forecast for Biomerica.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) released its quarterly earnings results on Tuesday, April, 14th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.03. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.35 million. Biomerica had a negative net margin of 51.37% and a negative return on equity of 67.54%. View Biomerica's earnings history.

What price target have analysts set for BMRA?

1 analysts have issued twelve-month price objectives for Biomerica's shares. Their forecasts range from $11.00 to $11.00. On average, they expect Biomerica's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 105.6% from the stock's current price. View analysts' price targets for Biomerica.

Has Biomerica been receiving favorable news coverage?

Media headlines about BMRA stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biomerica earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutBiomerica.

Are investors shorting Biomerica?

Biomerica saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 209,600 shares, a drop of 53.7% from the April 30th total of 452,500 shares. Based on an average trading volume of 1,710,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.5% of the shares of the company are sold short. View Biomerica's Current Options Chain.

Who are some of Biomerica's key competitors?

What other stocks do shareholders of Biomerica own?

Who are Biomerica's key executives?

Biomerica's management team includes the following people:
  • Mr. Zackary S. Irani, Chairman & CEO (Age 53)
  • Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 68)

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.50%), Heritage Investors Management Corp (0.39%), Creative Planning (0.17%), Morgan Stanley (0.16%) and Wells Fargo & Company MN (0.08%). View institutional ownership trends for Biomerica.

Which institutional investors are buying Biomerica stock?

BMRA stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Heritage Investors Management Corp, Creative Planning, Morgan Stanley, and Wells Fargo & Company MN. View insider buying and selling activity for Biomerica.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $5.35.

How big of a company is Biomerica?

Biomerica has a market capitalization of $52.91 million and generates $5.20 million in revenue each year. The company earns $-2,390,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Biomerica employs 54 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is www.biomerica.com.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.